Summarized by Masters of Longevity from Longevity Technology.
A healthtech funding and partnership update that previews commercialization plans for a new minimally invasive glucose microsensor. Read to learn what the article covers and why the deal matters for device rollout and future metabolic monitoring.
Key Takeaways
- Ascensia Diabetes Care led a $36 million Series B investment into the company and agreed to commercialize the microsensor in Europe.
- A 46-person study showed the microsensor tracked glucose for ten days with accuracy comparable to a leading commercial CGM.
- The company plans a pivotal study aiming for CE non-adjunctive approval so readings could guide insulin dosing without fingersticks.
